A humanized mouse that mounts mature class-switched, hypermutated and neutralizing antibody responses.

A humanized mouse that mounts mature class-switched, hypermutated and neutralizing antibody responses.

Publication date: Jun 25, 2024

Humanized mice are limited in terms of modeling human immunity, particularly with regards to antibody responses. Here we constructed a humanized (THX) mouse by grafting non-γ-irradiated, genetically myeloablated Kit mutant immunodeficient pups with human cord blood CD34 cells, followed by 17β-estradiol conditioning to promote immune cell differentiation. THX mice reconstitute a human lymphoid and myeloid immune system, including marginal zone B cells, germinal center B cells, follicular helper T cells and neutrophils, and develop well-formed lymph nodes and intestinal lymphoid tissue, including Peyer’s patches, and human thymic epithelial cells. These mice have diverse human B cell and T cell antigen receptor repertoires and can mount mature T cell-dependent and T cell-independent antibody responses, entailing somatic hypermutation, class-switch recombination, and plasma cell and memory B cell differentiation. Upon flagellin or Pfizer coronavirus disease 2019 mRNA vaccination, THX mice mount neutralizing antibody responses to Salmonella or severe acute respiratory syndrome coronavirus 2 Spike S1 receptor-binding domain, with blood incretion of human cytokines, including APRIL, BAFF, TGF-β, IL-4 and IFN-γ, all at physiological levels. These mice can also develop lupus autoimmunity after pristane injection. By leveraging estrogen activity to support human immune cell differentiation and maturation of antibody responses, THX mice provide a platform to study the human immune system and to develop human vaccines and therapeutics.

Open Access PDF

Concepts Keywords
Antibody Antibody
April Blood
Mutant Cells
Myeloid Class
Salmonella Develop
Differentiation
Humanized
Immune
Including
Lymphoid
Neutralizing
Receptor
Responses
System
Thx

Semantics

Type Source Name
drug DRUGBANK Estradiol
pathway REACTOME Immune System
disease IDO cell
disease MESH coronavirus disease 2019
disease VO vaccination
disease VO Severe acute respiratory syndrome coronavirus 2
disease IDO blood
drug DRUGBANK Binetrakin
disease MESH autoimmunity
disease VO injection

Original Article

(Visited 5 times, 1 visits today)